Document Detail

Antecedent hypertension and the effect of captopril on the risk of adverse cardiovascular outcomes after acute myocardial infarction with left ventricular systolic dysfunction: Insights from the Survival and Ventricular Enlargement Trial.
MedLine Citation:
PMID:  15309009     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Hypertension is a well-established risk factor for myocardial infarction (MI), but its prognostic importance in survivors of an acute MI is less clear. METHODS: We used Cox proportional hazards models to examine the risk of any major cardiovascular event (cardiovascular death, heart failure, recurrent MI, or stroke)-combined or individual components-and all-cause death and evaluate the efficacy of captopril in 906 patients with hypertension and 1325 patients without hypertension in the Survival and Ventricular Enlargement (SAVE) clinical trial. All patients had survived an acute MI with resultant left ventricular (LV) systolic dysfunction, but without overt heart failure, and were randomized within 3 to 16 days after the index MI to receive either captopril or placebo. The mean (+/- SD) follow-up period was 42 +/- 10 months. RESULTS: After adjustment for known risk factors, medication use at enrollment, and baseline systolic blood pressure, patients with hypertension had a significant increase in the risk of experiencing a combined cardiovascular event (47.7% vs 31.3%; hazard ratio [HR], 1.49; 95% CI, 1.28-1.74), cardiovascular death (23.4% vs 15.9%; HR, 1.40; 95% CI, 1.12-1.74), heart failure (27.7% vs 15.5%; HR, 1.64; 95% CI, 1.34-2.02), and all-cause death (27.4 vs 19.3%; HR, 1.25; 95% CI, 1.02-1.53), and a similar but statistically non-significant increase in the risk of non-fatal or fatal recurrent MI (17.4% vs 10.9%; HR, 1.27; 95% CI, 0.98-1.65), and non-fatal or fatal stroke (5.0% vs 3.6%; HR, 1.31; 95% CI, 0.81-2.09). Captopril resulted in similar benefits for both patients with and patients without hypertension. The number of combined cardiovascular events prevented for every 100 patients treated with captopril was 7.0 (95% CI, 0.5-13.5) in patients with hypertension and 7.5 (95% CI, 2.6-12.5) in patients without hypertension. CONCLUSIONS: In survivors of an acute MI with LV systolic dysfunction, antecedent hypertension was associated with a greater risk of subsequent adverse cardiovascular events, not directly explained by elevated blood pressure levels. Captopril use was beneficial in both patients with and patients without hypertension.
Satish Kenchaiah; Barry R Davis; Eugene Braunwald; Jean-Lucien Rouleau; Gilles R Dagenais; Bruce Sussex; Richard M Steingart; Edward J Brown; Gervasio A Lamas; David Gordon; Victoria Bernstein; Marc A Pfeffer;
Related Documents :
2896919 - Effect of intravenous nitrates on mortality in acute myocardial infarction: an overview...
9270949 - Prevalence, determinants, and misclassification of myocardial infarction in the elderly.
12238419 - Application of a cardiac arrest score in patients with sudden death and st segment elev...
17056319 - Impact of multivessel coronary disease on long-term mortality in patients with st-eleva...
18931449 - Study on the risk factors of postoperative hypoxemia in patients undergoing coronary ar...
20684999 - A comparison of st elevation versus non-st elevation myocardial infarction outcomes in ...
17586069 - Early cardiac remodeling after repair of sinus venosus atrial septal defect.
23334649 - Predictive utility of nt-pro bnp for infarct size and left ventricle function after acu...
12053679 - Acute cardiogenic shock immediately after successful intervention for failed thrombolysis.
Publication Detail:
Type:  Clinical Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  American heart journal     Volume:  148     ISSN:  1097-6744     ISO Abbreviation:  Am. Heart J.     Publication Date:  2004 Aug 
Date Detail:
Created Date:  2004-08-13     Completed Date:  2005-01-13     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0370465     Medline TA:  Am Heart J     Country:  United States    
Other Details:
Languages:  eng     Pagination:  356-64     Citation Subset:  AIM; IM    
Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Analysis of Variance
Angiotensin-Converting Enzyme Inhibitors / therapeutic use*
Blood Pressure / drug effects
Captopril / therapeutic use*
Cardiovascular Diseases / etiology*,  mortality
Hypertension / complications*,  drug therapy
Middle Aged
Myocardial Infarction / complications*,  drug therapy
Proportional Hazards Models
Risk Factors
Ventricular Dysfunction, Left / complications
Reg. No./Substance:
0/Angiotensin-Converting Enzyme Inhibitors; 62571-86-2/Captopril

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Is hormonal activation during exercise useful for risk stratification in patients with moderate cong...
Next Document:  Response of B-type natriuretic peptide to exercise in hypertensive patients with suspected diastolic...